The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the Society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy—from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for the Journal for Immunotherapy of Cancer, an outlet devoted to and created by today's leaders in the field.
Less than a year after its first issue, JITC was accepted to PubMed and PubMed Central! This is an exciting step in the evolution of JITC, as it now offers greater visibility and accessibility to all accepted articles.
As a way to say thank you to the dedicated Society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer Society members waived article processing charges for manuscripts accepted in 2015. To take advantage of this member benefit, contact SITC at +1 414-271-2456 or firstname.lastname@example.org for your member code.
SITC will be presenting two $1,000 USD awards for papers published in the Clinical/Translational and Basic Science sections by SITC members. Awards will be selected by the JITC editorial board and include the JITC Best Clinical Application Paper and JITC Best Basic Science Paper.
Winners will be announced at the SITC 30th Anniversary Annual Meeting Award Ceremony.
The journal welcomes submissions in the following areas and other related topics:
Basic Tumor Immunology
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses
Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach
Clinical/Translational Cancer Immunotherapy
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies
Clinical Trials Monitor
Announcements and updates of cancer immunotherapy clinical trials in progress. Includes perspectives and implications of late stage pivotal clinical trials results and new regulatory approvals. Articles may also focus on other pertinent regulatory issues to help define a road map for navigating the clinical trial landscape
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers
Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next
The Editorial Board is comprised of internationally recognized thought leaders in the field and experts in their content areas. They are also members of SITC and deeply committed to advancing the knowledge about, and integration of, cancer immunotherapy research into the clinical setting.